Pharsight

Zykadia is owned by Novartis.

Zykadia contains Ceritinib.

Zykadia has a total of 11 drug patents out of which 4 drug patents have expired.

Expired drug patents of Zykadia are:

US8188276
US8835430
US9416112
US9018204

Zykadia was authorised for market use on 18 March, 2019.

Zykadia is available in tablet;oral dosage forms.

Zykadia can be used as treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).

The generics of Zykadia are possible to be released after 02 February, 2032.

Application	Filing Date	Opposition Party	Legal Status
EP16167355A	2019-05-14	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16167355A	2019-04-25	Generics (UK) Ltd	Granted and Under Opposition
EP11806079A	2018-04-12	Generics (UK) Ltd	Revoked
EP11806079A	2018-04-10	Teva Pharmaceutical Industries Ltd	Revoked
EP12703670A	2016-03-10	Generics [UK] Limited	Opposition rejected
EP12703670A	2016-03-10	I P S Intellectual Property Services	Opposition rejected
EP12703670A	2016-03-08	Teva Pharmaceutical Industries Ltd	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188276	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (2 months ago)
US8835430	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (2 months ago)
US9416112	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (2 months ago)
US9018204	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (2 months ago)
US7893074	NOVARTIS	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	Apr, 2026 (3 years from now)
US8399450	NOVARTIS	Compounds and compositions as protein kinase inhibitors	Nov, 2027 (4 years from now)
US7964592	NOVARTIS	2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	Apr, 2028 (5 years from now)
US8039479	NOVARTIS	Compounds and compositions as protein kinase inhibitors	Jun, 2030 (7 years from now)
US9309229	NOVARTIS	Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine	Jan, 2032 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921	NOVARTIS	Compounds and compositions as protein kinase inhibitors	Nov, 2027 (4 years from now)
US8703787	NOVARTIS	Methods of using ALK inhibitors	Feb, 2032 (8 years from now)